Light Chain Bioscience

GlaxoSmithKline could find out this week whether the European Medicines Agency will recommend that its multiple myeloma drug belantamab mafodotin be approved in the EU, setting the company on course

A number of products at the final stages of review at the European Medicines Agency are finding out this week whether they have cleared a critical milestone in their journey to the EU market. They inc

Recent strategic product acquisitions have strengthened the hematology and immunology businesses of European mid-sized pharma company, Swedish Orphan Biovitrum AB (Sobi), and with several late-stage

Swedish Orphan Biovitrum AB (Sobi) has jumped on the mergers and acquisition merry-go-round to acquire Dova Pharmaceuticals Inc. , expanding its hematology franchise and commercial presence in the U